DJ AIM ImmunoTech Shares Drop 14% After Completing At-the-Market Facility
By Chris Wack
AIM ImmunoTech Inc. shares fell 14% to $2.37 after the company said it has completed its at-the-market facility and closed the ATM's equity distribution agreement.
The company said it believes that it has adequate funds to meet its anticipated operational cash needs and fund current clinical trials over the next two years.
AIM said it hopes to speed up its company-sponsored developmental programs in oncology, Covid, ME/CFS and Long Covid, by independently financing activities where situations call for swift action.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
February 05, 2021 10:12 ET (15:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.